|
Czech Republic Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Czech Republic Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for the Czech Republic.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Czech pharmaceutical and healthcare industry.
Competitive intelligence, Czech pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Czech market.
The Czech Republic Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Czech Republic Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Czech pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on the Czech Republic to test other views – a key input for successful budgeting and strategic business planning in the Czech pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Czech Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in the Czech Republic.
- Exploit The Latest Competitive Czech Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in the Czech Republic.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Czech Republic Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Czech Republic Pharmaceuticals And Healthcare Industry SWOT |
| Czech Republic Political SWOT |
| Czech Republic Economic SWOT |
| Czech Republic Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Czech Republic Pharmaceutical Business Environment Ratings |
| Limits To Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Intellectual Property Environment |
| Pricing And Reimbursement Issues |
| Healthcare Sector |
| Hospital Sector |
| Opposition to Health Fees |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Czech Republic's Drug Market Forecast Indicators, 2004-2013 |
| Key Growth Factors – Industry |
| Table: Czech Republic's Health Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Czech Republic – Economic Activity |
| Prescription Market Forecast |
| Table: Czech Republic – Prescription Market Indicators, 2004-2013 (US$mn unless otherwise indicated) |
| Patented Drug Market Forecast |
| Table: Patented Drugs Market Indicators, 2004-2013 |
| Generics Market Forecasts |
| Table: Czech Republic's Generics Market Forecast 2004-2013 |
| OTC Market Forecast |
| Table: OTC Drugs Market Indicators, 2004-2012 (US$mn unless otherwise stated) |
| Medical Device Forecast |
| Czech Republic Medical Device Market Forecast |
| Export/Import Forecasts |
| Table: Czech Republic's Pharmaceutical Trade Indicators, 2004-2013 (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Socio-Demographic Indicators |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Recent Company Developments |
| Research And Development Sector |
| Wholesale |
| Retail Sector |
Chapter - Company Monitor |
| Multinational Companies |
| AstraZeneca |
| Bristol-Myers Squibb |
| Sanofi-Aventis |
| Local Companies |
| Walmark |
| Zentiva (incorporating Sicomed) |
Chapter - Country Snapshot: Czech Republic Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Czech Republic Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
BMI forecasts that the Czech drug market will grow at a compound annual growth rate (CAGR) of 4.8% over the 2008-2013 period. Although this represents a fall on the 8.1% growth and 13.9% growth witnessed in 2008 and 2007 respectively, it is indeed encouraging in light of the economic turmoil in which many Eastern European countries now find themselves. In addition, growth levels at the end of 2007 were distorted by patients stockpiling medicines ahead of the introduction of co-payments at the beginning of 2008. While future healthcare reforms remain a key risk to our forecast scenario, an overall demand for more effective and modern treatments should continue to cause increased sales and prices. However, we believe the days of double-digit growth are over, in light of the Czech markets maturing status and increasingly negative pricing and reimbursement environment.
The biggest development of the quarter has seen French pharmaceutical Sanofi-Aventis receiving European Commission (EC) approval for its US$2.3bn acquisition of Czech generics firm Zentiva. EU antitrust regulators have ordered Sanofi-Aventis to divest 15 drugs in various countries due to their concerns over the level of risk associated with the deal. Regulators were particularly concerned that the deal could mean reduced choice and higher prices for hospitals, patients and governments in Central and Eastern Europe,. Sanofi has stressed that the sales will have only a limited impact on revenues, as the divested products collectively generated annual sales of approximately EUR18.0mn (US$23mn) in 2007.
Meanwhile, in January 2009, The Czech State Institute for Drug Control (SUKL) introduced a new system for prescribing medicines, allowing patients to obtain repeat prescriptions without needing to see a doctor. The system, which will allow doctors to send prescriptions via mobile phone using SMS, or email, means that patients will need only to be informed of the prescription's short identification code, following from which a patient will be able to collect their medicine from the pharmacy. Retailers are currently awaiting installation of connection with SUKL servers, which will allow them to verify prescriptions. Completion for most outlets is expected by the end of March 2009.
The Czech Republic has fallen to third place in Business Environment Rankings for the Central & Eastern European region. However, this has been largely due to faster improvement in scores for its regional neighbours, Greece and Slovakia. The Czech Republic is still let down by its sub-standard patent regime, which could harm the development of its biotech sector.
|
Czech Republic Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |